Hengrui Pharma's Zhang Lianshan: The gap in R&D levels between domestic pharmaceutical companies and foreign ones is rapidly narrowing

"In the past 20 years, Hengrui Pharma's practice in the field of new molecular design has fully demonstrated that the company possesses innovation capabilities and can produce many high-quality innovative drugs. Moving forward, the company's core direction is to upgrade from 'quantity' to 'higher quality', building a more solid foundation and channels for going global," said Zhang Lianshan, Global R&D President of Hengrui Pharma, at the International Investor Conference of the Shanghai Stock Exchange on November 13